Compare Stocks

Clough Global Dividend and Income Fund is a closed ended balanced mutual fund launched and managed by Clough Capital Partners L.P. The fund primarily invests in the public equity and fixed income markets across the globe. It seeks to invest in securities of companies operating across diversified sectors. For its fixed income portion, it invests in corporate and sovereign debt. It invest in fixed income securities having a maturity ranging from 30 days to over 30 years. The fund invests in non-U.S. markets primarily through liquid securities, including depositary receipts. Its equity portion primarily invests in stocks of small-cap and mid-cap companies. The fund employs a fundamental analysis with a bottom-up stock picking approach to make its investments. It primarily employs a theme-oriented investment approach which emphasizes on industry consolidation, technological change, an emerging shortage of a product or raw material which derives from a period of under-investment, and changes in government regulation or major economic or investment cycles. The fund's research process includes identifying shortages, global geographic growth opportunities, and unique global credit market opportunities. The fund was formerly known as Clough Global Allocation Fund. Clough Global Dividend and Income Fund was formed on April 27, 2004 and is domiciled in the United States.

GP Strategies Corp. provides training, e-Learning solutions, management consulting and engineering services. It operates through the following Geographic Segments: North America, EMEA and Emerging Markets (Latin America and Asia Pacific countries). It provides Workforce Transformation Services into three primary solution sets: Organizational Performance Solutions (OPS), Technical Performance Solutions (TPS) and Automotive Performance Solutions (APS). The company was founded in 1959 and is headquartered in Columbia, MD.

ShangPharma Corporation (ShangPharma) is a China-based holding company. The Company is a pharmaceutical and biotechnology research and development (R&D) outsourcing company. It provides a range of high-quality, integrated services across the drug discovery and development process to international and Chinese pharmaceutical and biotechnology companies. Its services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. It has a diversified and loyal global customer base. In March 2013, the Company completed the merger contemplated by the previously announced Agreement and Plan of Merger (the Merger Agreement), by and among the Company, ShangPharma Holdings Limited (Holdings), ShangPharma Parent Limited (Parent) and ShangPharma Merger Sub Limited (Merger Sub). As a result of the merger, the Company became a wholly owned subsidiary of Parent.

Special Opportunities Fund, Inc. is a close-ended balanced fund of funds launched and managed by Bulldog Investors, LLC. It invests in close-ended funds investing in public equity and fixed income markets. The fund employs a combination of value, opportunistic and special situations strategies to make its investments. It benchmarks the performance of its portfolio against the S&P 500 Index. The fund was previously known as Insured Municipal Income Fund, Inc. Special Opportunities Fund, Inc. was formed on February 18, 1993 and is domiciled in the United States.